Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, has announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of US$16 per share. All of the shares are being offered by Foghorn. In addition, Foghorn has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Foghorn’s common stock began trading on The Nasdaq Global Market on October 23, 2020 under the symbol “FHTX.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Foghorn, are expected to be approximately US$120 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 27, 2020, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by partners Pete Handrinos and Wesley Holmes, with associates Jennifer Yoon, Brian Yoon, and Michael Casagrande. Advice was also provided on tax matters by partner Jocelyn Noll, with associate Joseph Curran.